Artículos de revistas
Chronic Myeloid Leukemia - Development Of New Drugs [leucemia Mielóide Crônica - Novas Drogas Em Desenvolvimento]
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 30, n. SUPPL. 1, p. 32 - 36, 2008.
15168484
10.1590/S1516-84842008000500009
2-s2.0-55949105844
Autor
De Souza C.A.
Institución
Resumen
Chronic Myeloid Leukemia (CML) is a model of clinical and biological investigation that may be useful for other neoplastic diseases. The therapeutic response to imatinib as the front line therapy has changed concepts and procedures in CML and has created hope concerning new more potent drugs for this and other oncological diseases that have a similar mechanism of action. However, not all patients achieve this ideal situation. Thus, Baccarani et al. suggested that cases of failure of suboptimal response, as a precaution or in warning situations should be studied in order to develop differentiated new therapies earlier. Resistance to imatinib exists and may depend of several mechanisms. Delay in its use or the advanced phase of the disease are more frequently associated with imatinib resistance. In respect to the biological point of view, over expression of the BCR-ABL gene, additional genetics abnormalities and mutations that involve other regions of the molecule (P-Loop, A-Loop or kinase dominion) are the most important factors associated to imatinib resistance. Hence, new therapeutic options are necessary in order to overcome resistance and to act on other target cells. Currently, Dasatinib was approved in the US, Europe and Brazil. Nilotinib is in advanced phase III studies and was recently approved in the US. Both Dasatinib and Nilotinib have been approved for intolerant and refractory imatinib patients. Bosutinib, INNO - 406 as well as other TK, aurora kinase and histone deacetylase inhibitors are in clinical studies and probably will be available in the future. 30 SUPPL. 1 32 36 Baccarani, M., Saglio, G., Goldman, J., Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet (2006) Blood, 108, pp. 1809-1820 Hochhaus, A., Druker, B.J., Larson, R.A., (2007) IRIS 6-year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood, 110 (11), pp. 15a. , abstract 25 Kantarjian, H., Talpaz, M., O'Brien, S., High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (2004) Blood, 103, pp. 2873-2878 Hughes, T.P., Deininger, M.W., Hochhaus, A., Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results (2006) Blood, 108, pp. 28-37 Talpaz, M., Silver, R.T., Druker, B.J., Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid: Results of a phase 2 study (2002) Blood, 99, pp. 1928-1937 Sawyers, C.L., Hochhaus, A., Feldman, E., Gleevec (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study (2002) Blood, 99, pp. 3530-3539 Mahon, F.X., Belloc, C., Lagarde, V., MDR1 gene over expression confers resistance to imatinib mesylate in leukemia cell line models (2003) Blood, 101, pp. 2368-2373 Branford, S., Rudzki, Z., Walsh, S., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate binding loop (P-loop)are associated with a poor prognosis (2003) Blood, 102, pp. 276-283 Talpaz, M., Shah, N.P., Kantarjian, H., Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias (2006) New Engl J Med, 354, pp. 2531-2541 Hochhaus, A., Kantarjian, H.M., Baccarani, M., Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemiaafter failure of imatinib therapy (2007) Blood, 109, pp. 2303-2309 Guilhot, F., Apperley, J., De Souza, C.A., Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase (2007) Blood, 109, pp. 4143-4150 Kantarjian, H., Pasquini, R., Hamerschlak, N., Dasatinib or high dose-imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial (2007) Blood, 109, pp. 5143-5150 Hochhaus, A., Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure (2007) Expert Opin Pharmacother, 18, pp. 3257-3264 Kantarjian, H., Giles, F., Wunderle, L., Nilotinib in imatinib-resistant CML and Philadelphia-chromosome positive ALL (2006) New Engl J Med, pp. 2542-2551 Le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formely AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood. 2007 Dec10 [Epub ahead of print]Le Coutre, P., Giles, F., Apperley, J., Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance and intolerance (2007) Blood (ASH annual meeting abstract), 110, p. 471 Giles, F., Le Coutre, P., Bhalla, K.N., Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intorelant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) (2007) Blood (ASH annual meeting abstract), 110, p. 1029 Kantarjian, H., Hochhaus, A., Cortes, J., Nilotinib is highly active and safe in chronic myelogenous leukemia (CML-CP) patients with imatinib resistance or intolerance (2007) Blood (ASH annual meeting abstract), 110, p. 735 Weisberg, E., Manley, P.W., Breitenstein, W., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl (2005) Cancer Cell, 7, pp. 2542-2551 Shah, N.P., Tran, C., Lee, F.Y., Overriding imatinib resistance with a novel ABL kinase inhibitor (2004) Science, 305, pp. 399-401 Breccia M, Cannella L, Nanni M et al. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 207;118(3):162-4Puttini, M., Coluccia, A.M., Boschelli, F., In vitro and in vivo activity of SKI-606, a novel Scr-Abl inhibitor, against imatinib resistant Bcr-Abl+ neoplastic cells (2006) Cancer Res, 66, pp. 11314-11322 Cortes, J., Kantarjian, H.M., Baccarani, M., Phase 1/2 study of SKI-606, a dual inhibitor of Scr and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia relapsed, refractory or intolerant of imatinib (2006) Blood, 108, pp. 54a. , Abstract 168 Gambacorti-Passrini, C., Kantarjian, H., Bruemmendorf, T., Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BC CML and Ph+ ALL (2007) Blood (ASH annual meeting abstract), 110, p. 473 Cortes, J., Bruemmendorf, T., Kantarjian, H., Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) (2007) Blood (ASH annual meeting abstract), 110, p. 733 Carter, T.A., Wodicka, L.M., Shah, N.P., Inhibition of drug-resistant mutants of ABL, KIT and EGF receptor kinases (2005) Proc Natl Acad Sci USA, 102, pp. 11011-11016 Gumireddy, K., Baker, S.J., Cosenza, S.C., A non-ATP-competitive inhibitor of BCR/ABL overrides imatinib resistance (2005) Proc Nat Acad Sci USA, 102, pp. 1992-1997 Giles, F., Cortes, J., Jones, D., MK-0457 a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation (2007) Blood, 109, pp. 500-502 Fiskus, W., Pranpat, M., Bali, P., Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells (2006) Blood, 108, pp. 645-652 Copland, M., Richmond, L., Hamilton, A., BMS-214662 eliminates CML stem cells and is active against blast crisis cells expressing BCR-ABL kinase mutations (2006) Blood, 108, pp. 222a. , abstract 739 Cortes, J., Jabbour, E., Kantarjian, H., Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors (2007) Blood, 110, pp. 4005-4011